Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'Multiple Model' dosage design, Bayesian feedback and individualised target goals

Clinical Pharmacokinetics

Volumn 34, Issue 1, 1998, Pages 57-77

  Jelliffe, Roger W ^a,c   Schumitzky, Alan ^a   Bayard, David ^a   Milman, Mark ^a   Van Guilder, Michael ^a   Wang, Xin ^a   Jiang, Feng ^a   Barbaut, Xavier ^b   Maire, Pascal ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; BAYES THEOREM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE; DRUG EFFECT; DRUG ELIMINATION; DRUG MONITORING; DRUG THERAPY; FEEDBACK SYSTEM; PATIENT CARE; POPULATION MODEL; PRIORITY JOURNAL;

ANTI-ARRHYTHMIA AGENTS; ANTI-BACTERIAL AGENTS; BAYES THEOREM; DIGOXIN; DRUG MONITORING; DRUG THERAPY; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; STATISTICS, NONPARAMETRIC; THERAPEUTIC EQUIVALENCY; VANCOMYCIN;

EID: 0031985373     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199834010-00003     Document Type: Article

References (49)

1. Rowland M, Sheiner L, Steimer JL, editors. Variability in drug therapy: description, estimation, and control. New York: Raven Press, 1985
2. Reuning R, Sams R, Notari R. Role of pharmacokinetics in drug dosage adjustment: I. pharmacologic effects, kinetics, and apparent volume of distribution of digoxin. J Clin Pharmacol 1973; 13: 127-41
3. Sheiner L, Beal S, Rosenberg B, et al. Forecasting individual pharmacokineties. Clin Pharmacol Ther 1979; 26: 294-305
4. Aarons L. The estimation of population pharmacokinetic parameters using an EM algorithm. Comput Methods Programs Biomed 1993; 41: 9-16
5. Beal S, Sheiner L. NONMEM user's guide I: users basic guide. San Francisco: Division of Clinical Pharmacology, University of California, 1979
6. Sheiner L. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 1984; 15: 153-71
7. Beal S. Population pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metab Rev 1984; 15: 173-93
8. De Groot M. Probability and statistics. 2nd ed. Reading (MA): Addison-Wesley, 1986: 334-6
9. Spieler G, Schumitzky A. Asymptotic properties of extended least squares estimators with approximate models [technical report]. Los Angeles: Laboratory of Applied Pharmacokinetics, University of Southern California School of Medicine. 1992: 92-4
10. Spieler G, Schumitzky A. Asymptotic properties of extended least squares estimates with application to population pharmacokinetics. San Francisco: Proceedings of the American Statistical Society, Biopharmaceutical Section. 1993: 177-82
11. Vonesh E, Chinchilla V. Linear and nonlinear models for analysis of repeated measurements. New York: Marcel Dekker, 1997: 354-5
12. Rodman J, Silverstein K. Comparison of two stage (TS) and first order (FO) methods for estimation of population parameters in an intensive pharmacokinetic (PK) study. Clin Pharmacol Ther 1990; 47: 151
13. Maire P, Barbaut X, Girard P, et al. Preliminary results of three methods for population pharmacokinetic analysis (NONMEM, NPML, NPEM) of amikacin in geriatric and general medicine patients. Int J Biomed Comput 1994; 36: 139-41
14. Lindstrom M, Bates D. Nonlinear mixed-effects models for repeated measures data. Biometrics 1990; 46: 673-87
15. Vonesh E, Carter R. Mixed effects nonlinear regressions for unbalanced repeated measures. Biometrics 1992; 48: 1-17
16. Wakefield J, Smith A, Racine-Poon A, et al. Bayesian ananysis of linear and nonlinear population models. Applied Stats 1994; 43: 201-22
17. Davidian M, Gallant A. The nonlinear mixed effects model with a smooth random effects density. Biometrika 1993; 80: 475-88
18. Bertilsson L. Geographic/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995; 29: 192-209
19. Lindsay B. The geometry of mixture likelihoods: a general theory. Ann Statist 1983; 11: 86-94
20. Mallet A. A maximum likelihood estimation method for random coefficient regression models. Biometrika 1986; 73: 645-56
21. Schumitzky A. The nonparametric maximum likelihood approach to pharmacokinetic population analysis: proceedings of the 1993 Western Simulation Multiconference: simulation for health care. San Deigo: Society for Computer Simulation. 1993: 95-100
22. Schumitzky A. Nonparametric EM algorithms for estimating prior distributions. App Math Comput 1991; 45: 143-57
23. Hurst A, Yoshinaga M, Mitani G, et al. Application of a bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother 1990; 34: 1165-71
24. Bayard D, Milman M, Schumitzky A. Design of dosage regimens: a multiple model stochastic approach. Int J Biomed Comput 1994; 36: 103-15
25. Bayard D, Jelliffe R, Schumitzky A, et al. Precision drug dosage regimens using multiple model adaptive control: theory and application to simulated vancomycin therapy. In: Sridhar R, Srinavasa RK, Vasudevan L, editor. Selected topics in mathematical physics. Madras: Allied Publishers Inc. 1995: 407-26
26. Mallet A, Mentre F, Giles J, et al. Handling covariates in population pharmacokinetics with an application to gentamicin. Biomed Meas Infor Contr 1988; 2: 138-46
27. Taright N, Mentre F, Mallet A, et al. Nonparametric estimation of population characteristics of the kinetics of lithium from observational and experimental data: individualization of chronic dosing regimen using a new bayesian approach. Ther Drug Monit 1994; 16: 258-69
28. Jerling M. Population kinetics of antidepressant and neuroleptic drugs: studies of therapeutic drug monitoring data to evaluate kinetic variability, drug interactions, nonlinear kinetics, and the influence of genetic factors [Ph.D. thesis]. Stockholm: Karolinska Institute at Huddinge University Hospital, 1995: 28-9
29. D'Argenio D. Optimal sampling times for pharmacokinetic experiments. J Pharmacokin Biopharm 1981; 9: 739-56
30. Jelliffe R, Iglesias T, Hurst A, et al. Individualising gentamicin dosage regimens: a comparative review of selected models, data filling methods and monitoring strategies. Clin Pharmacokinet 1991; 21: 461-78
31. Jelliffe R, Schumitzky A, Van Guilder M, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic models, bayesian fitting, and adaptive control. Ther Drug Monit 1993; 15: 380-93
32. Jelliffe R, Maire P, Sattler F, et al. Adaptive control of drug dosage regimens: basic foundations, relevant issues, and clinical examples. Int J Biomed Comput 1994; 36: 1-23
33. Sheiner L, Beal S. Bayesian individualization of pharmacokinetics: simple implementation and comparison with nonbayesian methods. J Pharm Sci 71: 1344-8
34. Vozeh S, Berger M, Wenk M, et al. Rapid prediction of individual dosage requirements for lignocaine. Clin Pharmacokinet 1984; 9: 354-63
35. Sawchuk R, Zaske D. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokin Biopharm 1976; 4: 183-95
36. Zaske D, Bootman JL, Solem L, et al. Increased burn patient survival with individualized dosages of gentamicin. Surgery 1982; 91: 142-9
37. Jelliffe R. Explicit determination of laboratory assay error patterns: a useful aid in therapeutic drug monitoring: No. DM 89-4 (DM56). Drug Monit Toxicol 1989; 10 (4): 1-6
38. Nelder J, Mead R. A simplex method for function minimization. Comput J 1965; 4: 308-13
39. Caceci M, Cacheris W. Fitting curves to data: the simplex algorithm is the answer. BYTE Magazine 1984; 9: 340-62
40. Lainiotis D. Partitioning: a unifying framework for adaptive systems. Pt 1: estimation. Proc IEEE 1976; 64: 1126-43
41. Dodge W, Jelliffe R, Richardson CJ, et al. Population pharmacokinetic models: measures of central tendency. Drug Invest 1993; 5: 206-11
42. Bertsekas D. Dynamic programming: deterministic and stochastic models. Englewood Cliffs (NJ): Prentice-Hall, 1987: 144-6
43. Jelliffe R, Schumitzky A, Van Guilder M, et al. User manual for version 10.7 of the USC*PACK collection of PC programs. Los Angeles: Laboratory of Applied Pharmacokinetics, University of Southern California School of Medicine, 1995: 57-69
44. Destache C, Meyer K, Bittner M, et al. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Monit 1990; 12: 419-26
45. Destache C, Meyer S, Rowley K. Does accepting pharmacokinetic recommendations impact hospitalization?: a cost-benefit analysis. Ther Drug Monit 1990; 12: 427-33
46. Vinks AATMM, Evers NAEM, Mathot R, et al. Impact of goal-oriented model-based TDM of aminoglycosides on clinical outcome: a cost-effectiveness study [abstract]. Submitted for consideration for presentation at the 5th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology; 1997 Nov; Vancouver; 10-4
47. Jelliffe R, Buell J, Kalaba R. Reduction of digitalis toxicity by computer-assisted glycoside dosage regimens. Ann Int Med 1972; 77: 891-906
48. Rodman J, Jelliffe R, Kolb E, et al. Clinical studies with computer-assisted lidocaine therapy. Arch Int Med 1984; 144: 703-9
49. Van Guilder M, Leary R, Schumitzky A, et al. Nonlinear nonparametric population codeling on a supercomputer. Supercomputer 1997 Conference; 1997 Nov 17-20; San Jose (CA)